UAB Digital Repository of Documents 3 records found  Search took 0.00 seconds. 
1.
25 p, 635.6 KB CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome / Barba, Pere (Hospital Universitari Vall d'Hebron) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Qin (Memorial Sloan Kettering Cancer Center) ; Cho, Christina (Weill Cornell Medical College) ; Castro-Malaspina, Hugo (Weill Cornell Medical College) ; Devlin, Sean M (Memorial Sloan Kettering Cancer Center) ; Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ; Giralt, Sergio (Weill Cornell Medical College) ; Jakubowski, Ann A. (Weill Cornell Medical College) ; Caballero, Dolores (Hospital Universitario Salamanca (CAUSA/IBSAL)) ; Maloy, Molly (Memorial Sloan Kettering Cancer Center) ; Papadopoulos, Esperanza B. (Weill Cornell Medical College) ; Piñana, José Luis (Hospital Clínic Universitari (València)) ; Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ; Márquez-Malaver, Francisco J. (Hospital Virgen del Rocío Sevilla) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Solano, Carlos (Hospital Clínic Universitari (València)) ; López-Corral, Lucía (Hospital Universitario Salamanca (CAUSA/IBSAL)) ; Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ; Perales, Miguel-Angel (Weill Cornell Medical College) ; Universitat Autònoma de Barcelona
Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34 cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). [...]
2018 - 10.1016/j.bbmt.2017.12.804
Biology of Blood and Marrow Transplantation, Vol. 24 Núm. 5 (may 2018) , p. 964-972  
2.
8 p, 440.5 KB Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy / Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ; Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ; Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ; Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ; Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ; Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ; Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ; Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ; Al-Homsi, Ahmad Samer (NYU Langone Health) ; Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ; Bar, Merav (Fred Hutchinson Cancer Research Center) ; Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ; Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ; Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ; Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ; DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ; Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ; El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ; Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ; Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ; Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ; Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ; Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ; Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ; Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ; Inamoto, Yoshihiro (National Cancer Center Hospital) ; Jacobsohn, David A. (Children's National Medical Center) ; Jain, Tania (Johns Hopkins University School of Medicine) ; Johnston, Laura (Stanford University School of Medicine) ; Kanate, Abraham S. (West Virginia University) ; Kansagra, Ankit (UT Southwestern Medical Center) ; Kassim, Adetola (Vanderbilt University Medical Center) ; Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ; Kitko, Carrie L. (Vanderbilt University Medical Center) ; Knight-Perry, Jessica (University of Colorado School of Medicine) ; Kurtzberg, Joanne (Duke University School of Medicine) ; Liu, Hien (Moffitt Cancer Center) ; MacMillan, Margaret L (University of Minnesota Medical School) ; Mahmoudjafari, Zahra (University of Kansas Cancer Center) ; Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ; Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ; Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ; Nemecek, Eneida (Oregon Health & Science University) ; Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ; Oran, Betul (The University of Texas MD Anderson Cancer Center) ; Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ; Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ; Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ; Pusic, Iskra (Washington University School of Medicine) ; Riches, Marcie L. (University of North Carolina at Chapel Hill) ; Rodriguez, Cesar (Wake Forest University School of Medicine) ; Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ; Saad, Ayman (The Ohio State University. Division of Hematology) ; Shah, Nina (University of California San Francisco. Department of Medicine) ; Shaw, Peter J. (The Children's Hospital at Westmead) ; Shenoy, Shalini (Washington University School of Medicine) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Talano, Julie (Children's Hospital of Wisconsin) ; Verneris, Michael R. (University of Colorado School of Medicine) ; Veys, Paul (University College London. Great Ormond Street Hospital.) ; Wagner, John E. (University of Minnesota Medical School) ; Savani, Bipin N. (Vanderbilt University Medical Center) ; Hamadani, Mehdi (Medical College of Wisconsin) ; Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ; Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ; Universitat Autònoma de Barcelona. Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649  
3.
21 p, 278.8 KB Long-term prognosis for 1-year relapse-free survivors of CD34 cell-selected allogeneic hematopoietic stem cell transplantation : a landmark analysis / Cho, Christina (Weill Cornell Medical College, New York, NY, 10065, USA) ; Hsu, Meier (Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Maloy, Molly A. (Memorial Sloan Kettering Cancer Center) ; Avecilla, Scott T. (Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ; Barker, Juliet N. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Castro-Malaspina, Hugo (Weill Cornell Medical College, New York, NY, 10065, USA) ; Giralt, Sergio A. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Jakubowski, Ann A. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Koehne, Guenther (Weill Cornell Medical College, New York, NY, 10065, USA) ; Meagher, Richard C. (Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ; O'Reilly, Richard J. (Memorial Sloan Kettering Cancer Center) ; Papadopoulos, Esperanza B. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Ponce, Doris M. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Tamari, Roni (Weill Cornell Medical College, New York, NY, 10065, USA) ; van den Brink, Marcel R. M. (Weill Cornell Medical College, New York, NY, 10065, USA) ; Young, James W. (The Rockefeller University, New York, NY, 10065, USA) ; Devlin, Sean M. (Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ; Perales, Miguel-Angel (Weill Cornell Medical College, New York, NY, 10065, USA) ; Universitat Autònoma de Barcelona
CD34 selection significantly improves GVHD-free survival in allogeneic hematopoietic cell transplantation (allo-HSCT). Specific information regarding long-term prognosis and risk factors for late mortality after CD34-selected allo-HSCT is lacking, however. [...]
2017 - 10.1038/bmt.2017.197
Bone marrow transplantation, Vol. 52 (october 2017) , p. 1629-1636  

See also: similar author names
9 Giralt, Santiago
3 Giralt, Santiago.
83 Giralt, Sebastià
1 Giralt, Sebastià, Universitat Autònoma de Barcelona, http://orcid.org/0000-0003-3977-6722
83 Giralt, Sebastiá
1 Giralt, Sergio A.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.